| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8735385 | Hepatobiliary & Pancreatic Diseases International | 2017 | 8 Pages |
Abstract
Serum sST2 may act as a promising biomarker to assess severity and predict prognosis of patients with HBV-ACLF and help for the early identification and optimal treatment of HBV-ACLF patients at high risk of mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Hepatology
Authors
Shao-Wen Jiang, Peng Wang, Xiao-Gang Xiang, Rui-Dong Mo, Lan-Yi Lin, Shi-San Bao, Jie Lu, Qing Xie,